Biotech entity
All 1 tracked stories fall under one category: pharma. Agamree is most often covered alongside Catalyst Pharmaceuticals, which appears in 1 of these 1 story. Agamree appears in 1 tracked Biotech story from February 24, 2026. The tracked stories average 2 original sources each.
Last mentioned: Feb 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Agamree is most often covered alongside Catalyst Pharmaceuticals, which appears in 1 of these 1 story. Agamree appears in 1 tracked Biotech story from February 24, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Agamree. Shared-story counts are live from our verified record — not editorial picks.
Catalyst Pharmaceuticals (CPRX) and Root (ROOT) are scheduled to release their quarterly financial results this Wednesday, February 25. For Catalyst, the report will be a critical barometer for the commercial uptake of its newly launched DMD treatment, Agamree, and the continued stability of its flagship LEMS therapy, Firdapse.
Agamree is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
